Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Viljem Kovač) .

1 - 10 / 49
Na začetekNa prejšnjo stran12345Na naslednjo stranNa konec
1.
Radiology and Oncology now on PubMed and PubMed Central
Gregor Serša, Viljem Kovač, 2013, predgovor, uvodnik, spremna beseda

Objavljeno v DiRROS: 22.03.2024; Ogledov: 40; Prenosov: 15
.pdf Celotno besedilo (622,06 KB)

2.
Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting
Mirko Lekić, Viljem Kovač, Nadja Triller, Lea Knez, Aleksander Sadikov, Tanja Čufer, 2012, izvirni znanstveni članek

Povzetek: Background. Small cell lung cancer (SCLC) represents approximately 13 tomediansurvival of SCLC patients treated by specific therapy (chemotherapy andžor radiotherapy) with regard to the 18%months in patients treated with standard chemotherapy and radiotherapy. Inpresence or absence of brain metastases at the time of diagnosis. Patients and methods. All SCLC patients have been treated in a routine clinical practice and followed up at theUniversity Clinic Golnik in Slovenia. In the retrospective study the medical files from 2002 to 2007 were review. All patients with cytological or histological confirmed disease and eligible for specific oncological treatment were included in the study. They have been treated according to the guidelines valid at the time. Chemotherapy and regular followed-up were carried out at the University Clinic Golnik and radiotherapy at the Institute of Oncology Ljubljana. Results. We found 251 patients eligible for the study. The median age of them was 65 years, majoritywere male (67%), smokers or ex-smokers (98%), with performance status 0 to 1 (83%). At the time of diagnosis no metastases were found in 64 patients(25.5%) and metastases outside the brain were presented in 153 (61.0%). Brain metastases, confirmedby a CT scan, were present in 34 patients (13.5%), most of them had also metastases at other localisations. (Abstract truncated at 2000 characters)
Ključne besede: pljuča, rak (medicina), drobnocelični rak, metastaze, možgani
Objavljeno v DiRROS: 22.03.2024; Ogledov: 41; Prenosov: 19
.pdf Celotno besedilo (552,38 KB)

3.
Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia : population-based survey of 444 patients
Viljem Kovač, Matjaž Zwitter, Tina Žagar, 2012, izvirni znanstveni članek

Povzetek: Background. Malignant pleural mesothelioma is a rare tumour with increasing frequency throughout the world. Due to long latency after exposure to asbestos, restrictions in the production and use of asbestos have not yet alleviated the burden of mesothelioma. During the last decade, several trials confirmed the benefit of systemic treatment with drugs such as doublets with cisplatina and gemcitabine or pemetrexed for carefully selected patients in good performance status. The purpose of this survey was to assess the impact of systemic treatment for the whole national population of patients with mesothelioma. Patients and methods. A retrospective study included all patients in Slovenia with histologically confirmed diagnosis of malignant pleural mesothelioma in the period from 1974 till 2008. Data from the Cancer Registry of Slovenia were supplemented by review of clinical records of the Institute of Oncology in Ljubljana where virtually all non-surgical treatment for mesothelioma was performed. We analysed the incidence, treatment, and survival of patients treated in the era of infrequent chemotherapy (1974-2003,the first period) and after it (2004-2008, the second period). Results. The survey included 444 patients, of whom 325 and 119 were diagnosed in the first and second period, respectively. Joinpoint regression analysis showed that after 1995 the trend in crude incidence rates increased more rapidly; the annual change was 0.03 per 100,000 per year before 1995 and 0.06 per 100,000 per year after. There was clear male predominance (70%) throughout the period covered by the survey. The proportion of patients above 65 years of age increased from 41.8% to 54.6% for the first and second period, respectively (p = 0.02). With a total of 52 (11.7%) operated patients, surgical treatment was rare and used only for selected patients with early disease and without comorbidity, leading to their relatively long median survival of 13.6 months. Chemotherapy was applied to 56 (17.2%) and to 96 (80.7%) patients during the first and second period, respectively. While a variety of older drugs were used in the first period, the most common regimen in the second period (applied to 91 patients) was doublet of low-dose gemcitabine in prolonged infusion and cisplatin. For the whole population of patients regardless the mode of treatment, median survival was 7.4 and 12.6 months (p-value = 0.037) for the first and second period, respectively. Conclusions. Increasing incidence, male predominance and increased proportion of older patients confirm that the burden of mesothelioma persists in spite o fa 15-years old ban in the production of asbestos. Modern chemotherapy, and in particular treatment with low-dose gemcitabine in prolonged infusion and cisplatin significantly prolonged median survival of patients with malignant pleural mesothelioma in Slovenia.
Objavljeno v DiRROS: 21.03.2024; Ogledov: 57; Prenosov: 21
.pdf Celotno besedilo (588,42 KB)

4.
Editorial - the first Impact factor for Radiology and Oncology
Gregor Serša, Viljem Kovač, 2012, predgovor, uvodnik, spremna beseda

Objavljeno v DiRROS: 21.03.2024; Ogledov: 63; Prenosov: 21
.pdf Celotno besedilo (75,24 KB)

5.
Editorial - progress of Radiology and oncology
Gregor Serša, Viljem Kovač, 2011, predgovor, uvodnik, spremna beseda

Objavljeno v DiRROS: 18.03.2024; Ogledov: 54; Prenosov: 23
.pdf Celotno besedilo (200,36 KB)

6.
Progress of Radiology and oncology
Gregor Serša, Viljem Kovač, 2010, predgovor, uvodnik, spremna beseda

Objavljeno v DiRROS: 18.03.2024; Ogledov: 50; Prenosov: 21
.pdf Celotno besedilo (85,87 KB)

7.
3T MRI in evaluation of asbestos-related thoracic diseases : preliminary results
Janez Podobnik, Igor Kocijančič, Viljem Kovač, Igor Serša, 2010, izvirni znanstveni članek

Objavljeno v DiRROS: 15.03.2024; Ogledov: 59; Prenosov: 12
.pdf Celotno besedilo (842,57 KB)

8.
9.
10.
Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006
Lučka Debevec, Tina Jerič, Viljem Kovač, Marko Bitenc, Mihael Sok, 2009, izvirni znanstveni članek

Povzetek: Background. The aim of the study was to establish eventual progress in routine management of lung cancer patients over a ten-year period at University Clinic for Respiratory and Allergic Diseases Golnik, Slovenia, comparing the results of analysis of 345 patients, diagnosed in 1996 (with analysis performed in 2002), and 405 patients, diagnosed in 2006 (with analysis performed in 2008).Patients and methods. The patients of both analysed groups were of comparable age and number of patients in stage I and II, but there were relatively more females, patients with better performance status, more precise clinical staging and tumour histology in the 2006 group. The parameters used for assessing the progress of management were as follows: time period from admittance to diagnosis and to surgery; precision of staging; accordance of clinical and pathological staging in resected patients; percentage of exploratory thoracotomy; and use of new treatment modalities. The proportion of patients in selected/actual primary treatment modality and survival rate could also be used for assessing the progress. Results. Althoughunessential longer time from admittance to microscopic confirmed diagnosis increased from a mean 7.4 to 8.6 days in 2006 progress was established by the following: more precise clinical staging (stage I and II also A and B stage, TNM staging also in small-cell lung cancer patients); improved accordance with clinical and pathological staging in resected patients (46% against 58%); decreased percentage of exploratory thoracotomy (13% against 4%); increased use of multimodality therapy as primary treatment modality (radiotherapy/chemotherapy, neoadjuvant chemotherapy); newly performed radio frequency tumour ablation. The proportion in selected/actual surgery increased from 76% to 93% and median survival rate of all patients from 6.2 to 10.6 months. (Abstract truncated at 2000 characters)
Objavljeno v DiRROS: 08.03.2024; Ogledov: 70; Prenosov: 22
.pdf Celotno besedilo (80,75 KB)

Iskanje izvedeno v 0.28 sek.
Na vrh